Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
DaVita Inc. (NYSE: DVA) announced the preliminary results of its modified Dutch auction tender offer for up to $1.0 billion of its common stock, which concluded on September 14, 2020. A total of 8,000,679 shares were tendered at or below $88.00 per share, leading to an expected purchase at this maximum price for a total cost of approximately $704 million. This represents about 6.6% of the company's outstanding shares. DaVita plans to finance these purchases using cash on hand, with final results pending confirmation by the depositary.
DaVita Inc. has appointed Shawn Guertin as a new independent director, effective Sept. 15. Guertin brings nearly 35 years of health care experience, including senior roles at Aetna, Inc. and Coventry Health Care. His expertise in financial strategy and managed care aims to strengthen DaVita's efforts in transforming kidney care. DaVita's Board now includes ten directors, maintaining a diversity of 40% racial/ethnic and gender representation. The company operates 2,795 outpatient dialysis centers in the U.S., serving over 205,300 patients.
In response to Hurricane Laura, DaVita Kidney Care opened its dialysis centers across Texas, Louisiana, Alabama, and Mississippi to all patients needing treatment, ensuring continuity of care. The company has coordinated care for nearly 700 evacuated dialysis patients and prepared 150 centers ahead of the hurricane, deploying essential resources. Patients are advised to adhere to local boil water advisories due to potential flooding. With a commitment to quality care, DaVita aims to support vulnerable patients during this emergency.
DaVita Clinical Research (DCR) has initiated two clinical trials to explore the impact of COVID-19 on patients with end stage kidney disease (ESKD) undergoing dialysis. The studies aim to investigate the role of COVID-19 antibodies in future infections and the relationship between genetic markers and the severity of COVID-19 symptoms. Approximately 524,000 individuals in the U.S. require dialysis, placing them at increased risk for severe COVID-19. Findings from these studies are expected to be published in early 2021, contributing valuable insights into the virus's effects on this vulnerable population.
DaVita Inc. (NYSE: DVA) announced a modified "Dutch auction" tender offer for up to $1.0 billion of its common stock. The share price will range from $77.00 to $88.00 and the offer will expire at midnight on September 14, 2020. This tender offer allows shareholders to specify tender amounts and prices, with DaVita determining the lowest acceptable price. The purchase will be financed with cash and potentially through borrowings. The company emphasizes that the offer is subject to specific conditions and is not a solicitation to sell shares.
DaVita has launched an expanded program named Bridge to Your Dreams to support clinical teammates pursuing nursing degrees. The initiative offers resources for patient care technicians and nurses to advance their education, covering tuition and related costs. Participants will receive guidance from academic advisors and success coaches, aiming to address educational barriers in nursing. With an expected shortfall of registered nurses, DaVita's program is crucial for cultivating a skilled workforce in kidney care. The company operates 2,795 dialysis centers in the U.S., serving over 205,300 patients.
DaVita Inc. (NYSE: DVA) has appointed Paula A. Price as an independent director, effective September 1, 2020. Ms. Price brings over 30 years of financial and operational experience from various industries, including her recent role as CFO of Macy's, Inc. She has a strong background in capital allocation and a commitment to healthcare innovation. With her addition, the DaVita Board now has nine directors, achieving over 75% diversity. Ms. Price will also serve on the Audit Committee, enhancing the board's expertise amid DaVita's focus on improving patient care.
DaVita Inc. (NYSE: DVA) has priced its $1.5 billion offering of senior notes due 2031 at a coupon of 3.750%. Closing is scheduled for August 11, 2020. Proceeds will redeem existing $1.5 billion senior notes due 2025, with the redemption set for August 21, 2020. The offering is conducted under Rule 144A and Regulation S, and is not registered under the Securities Act. The release includes forward-looking statements regarding the offering and its use of proceeds, along with risk factors related to market conditions and business impacts from COVID-19.
DaVita Inc. (NYSE: DVA) has announced a private offering of $1.5 billion in senior notes due 2031, subject to market conditions. The proceeds will be used to redeem all outstanding 5.000% senior notes due 2025, totaling $1.5 billion. A notice of redemption for the 2025 notes will be issued, contingent on the completion of the new offering. The notes are being offered under Rule 144A and Regulation S of the Securities Act. Risks include market conditions affecting the offering and ongoing impacts from the COVID-19 pandemic.
During Q2 2020, DaVita (NYSE: DVA) reported consolidated revenues of $2.880 billion with an operating income of $410 million, achieving a 14.2% operating margin. The company focused on patient care amid the COVID-19 pandemic, enhancing safety through testing and telehealth. Diluted EPS from continuing operations was $1.62, up from $1.16 Y-o-Y. Operating cash flow reached $651 million. DaVita treats over 236,000 patients at around 3,082 centers. However, the company reported a $16 million loss on the sale of its vascular access business.